Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Niraparib, Abiraterone Acetate and Prednisone for MHSPC with Deleterious Homologous Recombination Repair Alterations
      Description

      This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

      Conditions
      Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationBRIP1 Gene MutationCHEK2 Gene MutationFANCA Gene MutationPALB2 Gene MutationRAD51B Gene MutationRAD54L Gene Mutation
      Talk to us
      TERMINATED
      A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
      Description

      A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

      Conditions
      Solid Tumor
      Talk to us